Lymphocyte apoptosis: Induction by gene transfer techniques

Gene Therapy

Volumn 4, Issue 4, 1997, Pages 296-302

  Ebert, O ^a,b   Finke, S ^a   Salahi, A ^a   Herrmann, M ^a   Trojaneck, B ^a   Lefterova, P ^a   Wagner, E ^c   Kircheis, R ^c   Huhn, D ^a   Schriever, F ^a   Schmidt Wolf, I G H ^a,d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Gene therapy; Gene transfer; Lymphocytes

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 7; MONOCLONAL ANTIBODY CD3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA TRANSFECTION; ELECTROPORATION; GENE TRANSFER; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; METHODOLOGY; PRIORITY JOURNAL; RETROVIRUS;

EID: 8244259179     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300394     Document Type: Article

References (45)

1. Miller AR et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviral mediated gene transfer: comparison of immunologic properties with interleukin-2. Blood 1993; 82: 3686-3694.
2. Schmidt-Wolf G, Schmidt-Wolf ICH. Cytokines and clinical gene therapy. Eur J Immunol 1995; 25: 1137-1140.
3. Rosenberg SA, Aebersold P, Cornetta K. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. New Engl J Med 1990; 323: 570-578.
4. Hwu P et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor alpha cDNA for the gene therapy of cancer in humans. J Immunol 1993; 150: 4104-4115.
5. Cann AJ, Koyanagi Y, Chen ISY. High effiency transfection of primary human lymphocytes and studies of gene expression. Oncogene 1988; 3: 123-128.
6. Burkholder JK, Decker J, Yang NS. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer. J Immunol Meth 1993; 165: 149-156.
7. Buschle M et al. Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. Hum Gene Ther 1995; 6: 753-761.
8. Mehta BA, Schmidt-Wolf IGH, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells. Blood 1995; 86: 3493-3499.
9. Schmidt-Wolf IGH et al. Propagation of large numbers of T cells with natural killer cells markers. Br J Haematol 1994; 87: 453-458.
10. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696.
11. Csipai M et al. Effects of interleukin-7 on proliferation of tumor cells. Cancer Res Ther Control 1996; 5: 11-16.
12. Lynch DH, Miller RE. Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 1990; 145: 1983-1990.
13. Alderson MR, Sassenfeld HM, Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine activated killer cells from human peripheral blood. J Exp Med 1990; 172: 577-587.
14. Lynch DH, Namen AE, Miller RE. In vivo evaluation of the effects of mterleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur J Immunol 1991; 21: 2977-2985.
15. Koopman G et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
16. Kerr JF, Wyllie AH, Currie AR. Apoptosis a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
17. Hock H, Dorsch M, Diamantstein T, Blankenstein T. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291-1298.
18. Cotton M et al. Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary cells in the presence of adenovirus. Gene Therapy 1994; 1: 1-8.
19. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251-1254.
20. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991; 353: 858-861.
21. Boehme SA, Lenardo MJ. Ligand-induced apoptosis of mature T lymphocytes occurs at distinct stages of the cell cycle. Leukemia 1993; 7: 45-49.
22. Boehme SA, Lenardo MJ. Propriocidal apoptosis of mature T lymphocytes occurs at the S phase of the cell cycle. Eur J Immunol 1993; 23: 1552-1560.
23. Ortaldo JR, Mason AT, O'Shea JJ. Receptor-induced death in human natural killer cells: involvement of CD 16. J Exp Med 1995; 181: 339-344.
24. Azzoni L, Anegon I, Calabretta B, Perussia B. Ligand binding to FcyR induces c-myc-dependent apoptosis in IL-2-stimulated NK cells. J Immunol 1995; 154: 491-499.
25. Taga K et al. Target-induced death by apoptosis in human lymphokine-activate natural killer cells. Blood 1996; 87: 2411-2418.
26. McConkey DJ, Jondal M, Orrenius S. Cellular signaling in thymocyte apoptosis. Semin Immunol 1992; 4: 371-377.
27. Wylie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984; 142: 67-77.
28. Armant M, Delespesse G, Sarfati M. II-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 1995; 85: 331-337.
29. Naume B, Gately M, Espevik T. A comparative study of IL-12-, IL-2- and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992; 148: 2429-2436.
30. Tos AG, Cignetti A, Rovrea G, Foa R. Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect. Blood 1996; 87: 2486-2495.
31. Treisman J et al. Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid. Cell Immunol 1994; 156: 448-457.
32. Goldfeld AE et al. TNF-alpha gene transcription is rapidly induced by anti-immunoglobulin and blocked by cyclosporine A and FK506 in human B cells. Proc Natl Acad Sci USA 1992; 89: 12198-12201.
33. Goldfeld AE et al. Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells. J Exp Med 1994; 180: 763-768.
34. Tsai EY et al. TNF alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Cell Biol 1996; 16: 459-167.
35. Bregamaschi G et al. TNF alpha down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with AMI,. Leukemia 1990; 4: 426-430.
36. Koo AS et al. The expression of C-jun and junB mRNA in renal cell cancer and in vitro regulation by TGF beta 1 and TNF alpha 1. J Urol 1992; 148: 1314-1318.
37. Manchester KM, Heston WD, Donner DB. Tumor necrosis factor-induced cytotoxicity is accompanied by intracellular mitogenic signals in ME-180 human cervical carcinoma cells. Biochem J 1993; 290: 185-190.
38. + cells via p55 TNFα receptors. Blood 1994; 84: 2506-2514.
39. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon Lysis of natural killer-resistant fresh solid tumor cells by TL-2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
40. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986; 233: 1318-1321.
41. Schmidt-Wolf IGH et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-149.
42. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and gene therapy. Immunol Today 1995; 16: 173-175.
43. Rosenberg SA et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin 2. JAMA 1994; 271: 907-913.
44. Sparano JA et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with Interferon alpha 2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-1977.
45. Gotten M, Wagner E. Nonviral approaches to gene therapy. Curr Opin Biotech 1993; 4: 705-710.